| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/10/2005 | WO2005011648A2 Use of cyclic bioisosteres of purine system derivatives for the treatment diseases caused by disorders of nitrergic and dopaminergic systems |
| 02/10/2005 | WO2005011645A2 Selected betaines and their uses |
| 02/10/2005 | WO2005011644A1 Transdermal warfarin-containing delivery system |
| 02/10/2005 | WO2005011642A1 Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent |
| 02/10/2005 | WO2005011639A2 Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use |
| 02/10/2005 | WO2005011638A2 Methods for the stabilization of atorvastatin |
| 02/10/2005 | WO2005011636A2 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 02/10/2005 | WO2005011634A1 Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| 02/10/2005 | WO2005011618A2 Methods for the treatment of male and female sexual dysfunction |
| 02/10/2005 | WO2005011617A2 Transmucosal dosage forms for brain-targeted steroid chemical delivery systems |
| 02/10/2005 | WO2005011615A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011614A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011613A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011611A2 Bicyclic compounds and compositions as pdf inhibitors |
| 02/10/2005 | WO2005011610A2 Neurodegenerative protein aggregation inhibition methods and compounds |
| 02/10/2005 | WO2005011609A2 Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
| 02/10/2005 | WO2005011608A2 PHARMACEUTICAL COMPOSITION COMPRISING A NON-GLUCOCORTICOID STEROID AND A cAMP INHIBITOR |
| 02/10/2005 | WO2005011607A2 Treatment of cancers expressing p95 erbb2 |
| 02/10/2005 | WO2005011604A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011603A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011602A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011601A2 6-menbered heteroaryl compounds for the treatment of neurodegenerative disorders |
| 02/10/2005 | WO2005011598A2 Leukemia treatment method and composition |
| 02/10/2005 | WO2005011597A2 Compounds and compositions as protein kinase inhibitors |
| 02/10/2005 | WO2005011595A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011594A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011593A2 Improved binding of pantoprazole to the acid pump |
| 02/10/2005 | WO2005011592A2 Substituted indazole-o-glucosides |
| 02/10/2005 | WO2005011591A2 Method for the treatment of sleep disorders |
| 02/10/2005 | WO2005011588A2 Polymorphs of butylated hydroxy anisole |
| 02/10/2005 | WO2005011586A2 Treatment and preventi0n of cardiovascular events |
| 02/10/2005 | WO2005011583A2 Treatment of allergic rhinitis and asthma |
| 02/10/2005 | WO2005011581A2 Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 02/10/2005 | WO2005011579A2 Treatment of dependence withdrawal |
| 02/10/2005 | WO2005011577A2 Methods for treating, preventing, or inhibiting injuries, cell membrane stabilization, and calcium mobilization using pseudopterosin compounds |
| 02/10/2005 | WO2005011572A2 Combination of drugs for the treatment of neoplasms |
| 02/10/2005 | WO2005011565A2 Antimycosic nail varnish |
| 02/10/2005 | WO2005011526A1 Osmium compounds for reduction of adverse inflammation |
| 02/10/2005 | WO2005011472A2 Reduction of adverse inflammation |
| 02/10/2005 | WO2004112716A3 Prodrugs of heteroaryl compounds |
| 02/10/2005 | WO2004112701A3 Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/10/2005 | WO2004110415A3 Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments |
| 02/10/2005 | WO2004110354A3 Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| 02/10/2005 | WO2004105794A3 Continuous dosing regimen with abt-751 |
| 02/10/2005 | WO2004105756A3 Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| 02/10/2005 | WO2004105696A3 Combination therapy for the treatment of neoplasms |
| 02/10/2005 | WO2004098612A3 Calcitriol analogs of uses thereof |
| 02/10/2005 | WO2004098564A3 Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide |
| 02/10/2005 | WO2004098543A3 Use of oligogalacturonide-type oligosaccharides in cosmetic, food or dermatological compositions in order to stimulate epidermal cell differentiation |
| 02/10/2005 | WO2004096823A3 Novel ketolide derivatives |
| 02/10/2005 | WO2004093903A3 Methods and compositions for immunomodulation using cd1 antigens |
| 02/10/2005 | WO2004093856A3 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia |
| 02/10/2005 | WO2004087652A3 Imidazotriazine compounds |
| 02/10/2005 | WO2004087117A3 Use of cyclic acetals/ketals for improved penetration of active substances into cells and organs |
| 02/10/2005 | WO2004082699A3 Use of incense or hydrogenation products for preventing and/or treating a cerebral ischemia and/or cerebral traumatic lesion |
| 02/10/2005 | WO2004080933A3 Isolation of lutein from alfalfa |
| 02/10/2005 | WO2004070034A3 Oligonucleotides directed against a survivin gene and use thereof |
| 02/10/2005 | WO2004062605A3 Method of achieving accelerated weight loss by administration of a weight loss accelerating agent to a dieting mammal |
| 02/10/2005 | WO2004060305A3 Anti-cancer medicaments |
| 02/10/2005 | WO2004054507A3 Indolizine compounds |
| 02/10/2005 | WO2004037207A3 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 02/10/2005 | WO2004035032A3 Pharmaceutical formulations of camptothecine derivatives |
| 02/10/2005 | WO2004032826A8 Process for preparing tannate tablet capsule or other solid dosage forms |
| 02/10/2005 | WO2003086175A8 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/10/2005 | WO2003050295A3 Assays and implements for determining and modulating hsp90 binding activity |
| 02/10/2005 | WO2000024869A9 Methods for modulating cell fusion |
| 02/10/2005 | US20050033522 Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
| 02/10/2005 | US20050033417 Coating for controlled release of a therapeutic agent |
| 02/10/2005 | US20050033414 Drug-eluting stent with multi-layer coatings |
| 02/10/2005 | US20050033261 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 02/10/2005 | US20050033081 Treating an animal for parasites |
| 02/10/2005 | US20050033067 cis-fused tetracyclic alcohol intermediates, the methanamine end-products, the methanamine end-products for use as a medicine, in particular as CNS active medicines |
| 02/10/2005 | US20050033066 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/10/2005 | US20050033065 Transdermal therapeutic system which contains a D2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
| 02/10/2005 | US20050033059 Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| 02/10/2005 | US20050033057 Thiazoline acid derivatives |
| 02/10/2005 | US20050033055 Edg receptor agonists |
| 02/10/2005 | US20050033052 Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis |
| 02/10/2005 | US20050033051 treatment of RNA viral infections such as HCV, HBV, small pox, Ebola, polio, West Nile, Coxsackie A and B, Rhino, and Echo viral infection using modified nucleotides; viricides |
| 02/10/2005 | US20050033048 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
| 02/10/2005 | US20050033041 Method of purifying moxidectin through crystallization |
| 02/10/2005 | US20050033034 Anti-t cell immunotoxin fusion protein and its therapeutic use |
| 02/10/2005 | US20050033026 Immunoconjugates for the treatment of tumours |
| 02/10/2005 | US20050032914 Lutein/zeaxanthin for glare protection |
| 02/10/2005 | US20050032912 Inhalation formulation of a suspension of the anaesthetic agent such as enflurane, desflurane, propofol in aqueous medium; without the problem of condensation of the anaesthetic within the administration apparatus and/or delivery tubes to the patient |
| 02/10/2005 | US20050032911 Alcoholism; gastrointestinal disorders, Crohn's disease, antiulcer agents induced by alcoholism |
| 02/10/2005 | US20050032910 Including keloid and hypertrophic scars; use in hydroalcoholic solutions and hydroalcoholic gels |
| 02/10/2005 | US20050032909 Treatment of mastalgia with 4-hydroxy tamoxifen |
| 02/10/2005 | US20050032908 Methods for treating metabolic syndrome |
| 02/10/2005 | US20050032905 Water soluble liquid solution of (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, a sweetening agent and an antimicrobial agent; antimuscarinic activity |
| 02/10/2005 | US20050032904 Such as terbinafine, butenafine and naftifine; use treating cancer; combination with other chemotherapeutic agents such as nocodazole |
| 02/10/2005 | US20050032901 (-)-Hydroxycitric acid for controlling inflammation |
| 02/10/2005 | US20050032900 For topical administration, without the presence of conventional oil in water (O/W) emulsifying agent; percutaneous delivery of ibuprofen is improved by using a skin penetration enhancer, such as 2-n-nonyl-1,3-dioxolane or decanal, dimethyl acetal, as the oily phase of the emulsion |
| 02/10/2005 | US20050032899 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 02/10/2005 | US20050032898 Oral amino acid composition |
| 02/10/2005 | US20050032896 Use of synthetic retinoic acid in form of 13-cis vitamin A for treatment of autism |
| 02/10/2005 | US20050032895 Medicament for the treatment of viral skin and tumour diseases |
| 02/10/2005 | US20050032894 Method for manufacturing calcium gluconolcatate compositions, processes and uses |
| 02/10/2005 | US20050032893 For topical administration; (N,N-dimethylamino)isopropyl propylene glycol heptadecanoate for example; penetration enhancers have hydrophobic fatty acyl group and hydrophilic dimethylamino and alkylene glycol diester groups |
| 02/10/2005 | US20050032892 Compositions, kits, and methods for treating gastrointestinal conditions |